醫藥股普遍受壓 騰盛博藥及開拓藥業挫9.5%-13% 中生製藥回升5.5%
恆指現報17,271,反覆回升70點或0.4%,總成交額525億元。
醫藥股今天普遍受壓,開拓藥業-B(09939.HK)跌破10天線(2.99元),最低見2.77元,現報2.85元,急挫13%。騰盛博藥-B(02137.HK)挫9.5%報2.68元,股價失守10天線(2.79元)。
信達生物(01801.HK)早段曾升至47.85元,之後掉頭向下,現跌6%報43.9元,股價失守20天線(45.45元)。聯邦制藥(03933.HK)連跌第五天兼失守50天線(7.75元),今天高低見7.8元/7.32元,現報7.4元,跌4.88%。藥明巨諾-B(02126.HK)跌5.9%報2.56元。三葉草生物-B(02197.HK)跌5.5%報0.69元。
藥明康德(02359.HK)、藍籌翰森(03692.HK)、康龍化成(03759.HK)、再鼎醫藥(09688.HK)及藍籌藥明生物(02269.HK)跌逾1%。
然而,藍籌中生製藥(01177.HK)扭轉兩連跌,股價回升5.5%報3.63元。百濟神州(06160.HK)第三季扭虧轉賺2.15億美元,大行普遍維持正面評級,該股高低見121.6/115.8元,現報118.8元,反覆升1.5%。神威藥業(02877.HK)、君實生物(01877.HK)及維亞生物(01873.HK)升逾1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.